CX3CL1 and CX3CR1 in lesion mechanism of atherosclerotic heart diseases

doi:10.3969/j.issn.1673-8640.2016.011.017

Abstract

Abstract:

Fractalkine（CX3CL1） and its specific receptor CX3C chemokine receptor1（CX3CR1）,CX3CL1-CX3CR1 axis are all involved in the formation and development of atherosclerosis,which change the plaque composition and stability of plaques. CX3CR1 V249I and CX3CR1 T280M are associated with coronary artery lesions. In atherosclerotic plaque,CX3CL1 and CX3CR1 were expressed by vascular smooth muscle cells（VSMC） and monocytes/macrophages. Interaction between vascular smooth muscle cells（VSMC） and monocyte needs CX3CL1-CX3CR1 axis,and this mutual effect regulates the survival and differentiation of monocyte. Through a series of mechanism,such as involved nuclear factor-kappa B（NF-κB）,activated protein-1（AP-1） and signal transducers and activators of transcription（STAT） 1/STAT3,resistin up-regulates the expressions of CX3CL1 and CX3CR1,and generates pro-inflammatory state of smooth muscle cells. Serum CX3CL1 level is increased in patients with unstable coronary artery diseases and patients with severe coronary artery lesions. Serum CX3CR1 level is increased in patients with coronary artery stenosis,which is not associated with the degree of coronary artery stenosis. The related study on CX3CL1/CX3CR1 shows the potential mechanism and pathogenicity effect of some inflammatory mediators in atherosclerotic heart diseases,so as to provide a reference for clinical treatment strategies and drug intervention studies.

Key words: Fractalkine, CX3C chemokine receptor 1, Atherosclerosis, Coronary artery diseases, Monocytes

CLC Number:

R446.1

LI Yongshu, ZHANG Baohuan, JIA Kegang, LIU Junfeng. CX3CL1 and CX3CR1 in lesion mechanism of atherosclerotic heart diseases[J]. Laboratory Medicine, 2016, 31(11): 1002-1010.

Figures/Tables 3

References 51

1	赵琰枫,冯晓燕,张贺秋. RANTES和Eotaxin与结核病[J]. 检验医学,2015,30(10):1048-1052.
2	WHITE GE,GREAVES DR.Fractalkine:a survivor's guide:chemokines as antiapoptotic mediators[J]. Arterioscler Thromb Vasc Biol,2012,32(3):589-594.
3	APOSTOLAKIS S,SPANDIDOS D.Chemokines and atherosclerosis:focus on the CX3CL1/CX3CR1 pathway[J]. Acta Pharmacol Sin,2013,34(10):1251-1256.
4	FLIERL U,BAUERSACHS J,SCHFER A.Modulation of platelet and monocyte function by the chemokine fractalkine(CX3 CL1) in cardiovascular disease[J]. Eur J Clin Invest,2015,45(6):624-633.
5	KUMAR AH,MARTIN K,TURNER EC,et al.Role of CX3CR1 receptor in monocyte/macrophage driven neovascularization[J]. PLoS One,2013,8(2):e57230.
6	FLIERL U,SCHFER A.Fractalkine-a local inflammatory marker aggravating platelet activation at the vulnerable plaque[J]. Thromb Haemost,2012,108(3):457-463.
7	ESCHER F,VETTER R,KÜHL U,et al. Fractalkine in human inflammatory cardiomyopathy[J]. Heart,2011,97(9):733-739.
8	POUPEL L,COMBADIERE C.Atherosclerosis:on the trail of chemokines[J]. Biol Aujourdhui,2010,204(4):285-293.
9	石磊,孙鲁宁,顾鹏毅,等. 趋化因子受体CX3CR1基因多态与中国北方人群脑梗死的关系[J]. 中风与神经疾病杂志,2012,29(5):434-438.
10	肖宏凯,陈柏荣,黄茵,等. CX3CR1基因249V/I 多态性与早发冠心病及血脂比值的相关性[J]. 中国动脉硬化杂志,2014,22(8):827-830.
11	WU J,YIN RX,LIN QZ,et al.Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis:a meta-analysis[J]. Dis Markers,2014,2014:913678.
12	MORGAN TM,XIAO L,LYONS P,et al.Investigation of 89 candidate gene variants for effects on all-cause mortality following acute coronary syndrome[J]. BMC Med Genet,2008,9:66.
13	MATZHOLD EM,TRUMMER O,GRÜNBACHER G,et al. Association of polymorphisms in the chemokine receptor CX3CR1 gene with coronary artery disease[J]. Cytokine,2009,47(3):224-227.
14	肖宏凯,金莉子,谢桂庭,等. CX3CR1基因多态性与冠心病的相关性[J]. 中国动脉硬化杂志,2010,18(12):993-995.
15	SINGH N,RAI H,SINHA N,et al.Association of V249I and T280M polymorphisms in the chemokine receptor CX3CR1 gene with early onset of coronary artery disease among North Indians[J]. Genet Test Mol Biomarkers,2012,16(7):756-760.
16	SINGH N,SINHA N,KUMAR S,et al.Polymorphism in chemokine receptor genes and risk of acute myocardial infarction in North Indian population[J]. Mol Biol Rep,2012,39(3):2753-2759.
17	PUCCI S,MAZZRELLI P,ZONETTI MJ,et al.CX3CR1 receptor polymorphisms,Th1 cell recruitment,and acute myocardial infarction outcome:looking for a link[J]. Biomed Res Int,2013,2013:451349.
18	冯皓,郭葆玉. 趋化因子受体CX3CR1的分子结构及生物学功能[J]. 国外医学(分子生物学分册),2002,24(6):378-380.
19	NASIBULLIN TR,YAGAFAROVA LF,YAGAFAROV IR,et al.Combinations of polymorphic markers of chemokine genes,their receptors and acute phase protein genes as potential predictors of coronary heart diseases[J]. Acta Naturae,2016,8(1):111-116.
20	GOLBUS JR,STITZIEL NO,ZHAO W,et al.Common and rare genetic variation in CCR2,CCR5,or CX3CR1 and risk of atherosclerotic coronary heart disease and glucometabolic traits[J]. Circ Cardiovasc Genet,2016. [Epub ahead of print]
21	STOLLA M,PELISEK J,VON BRÜHL ML,et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1[J]. PLoS One,2012,7(8):e43572.
22	WHITE GE,MCNEILL E,CHANNON KM,et al.Fractalkine promotes human monocyte survival via a reduction in oxidative stress[J]. Arterioscler Thromb Vasc Biol,2014,34(12):2554-2562.
23	LIU Y,IMANISHI T,IKEJIMA H,et al.Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction[J]. Circ J,2010,74(12):2585-2591.
24	FONOVIC UP,JEVNIKAR Z,KOS J.Cathepsin S generates soluble CX3CL1(fractalkine) in vascular smooth muscle cells[J]. Biol Chem,2013,394(10):1349-1352.
25	HERLEA-PANA O,YAO L,HEUSER-BAKER J,et al.Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression[J]. Cardiovasc Res,2015,106(2):324-337.
26	SHAH R,MATTHEWS GJ,SHAH RY,et al.Serum fractalkine(CX3CL1) and cardiovascular outcomes and diabetes:findings from the chronic renal insufficiency cohort(CRIC) study[J]. Am J Kidney Dis,2015,66(2): 266-273.
27	MARTYNOWICZ H,JANUS A,NOWACKI D,et al.The role of chemokines in hypertension[J]. Adv Clin Exp Med,2014,23(3):319-325.
28	WHITE GE,TAN TC,JOHN AE,et al.Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling[J]. Cardiovasc Res,2010,85(4):825-835.
29	金元哲,雷明明,颜冰,等. 趋化因子FKN对人外周血单个核细胞IL-8表达的影响及ERK、PI3K和NF-κB在其中的作用[J]. 大连医科大学学报,2014,43(2):124-128.
30	SZUKIEWICZ D,WOJCIECHOWSKA M,BILSKA A,et al.Aspirin action in endothelial cells:different patterns of response between chemokine CX3CL1/CX3CR1 and TNF-α/TNFR1 signaling pathways[J]. Cardiovasc Drugs Ther,2015,29(3):219-229.
31	ZHOU R,GONG AY,CHEN D,et al.Histone deacetylases and NF-κB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503[J]. PLoS One,2013,8(5):e65153.
32	阿曼古丽·如则,赵一蔚,古力热巴·夏依买旦,等. p38抑制剂对低剪切应力诱导的人脐静脉内皮细胞株Fractalkine蛋白表达的影响[J]. 新疆医科大学学报,2016,39(3):293-297.
33	GREENE JA,PORTILLO JA,LOPEZ CORCINO Y,et al.CD40-TRAF signaling upregulates CX3CL1 and TNF-α in human aortic endothelial cells but not in retinal endothelial cells[J]. PLoS One,2015,10(12):e0144133.
34	ZHANG H,GOU C,WU D,et al.Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression[J]. PLoS One,2012,7(7):e41147.
35	ZHANG H,GUO C,ZHANG A,et al.Effect of S-aspirin,a novel hydrogen-sulfide-releasing aspirin(ACS14),on atherosclerosis in apoE-deficient mice[J]. Eur J Pharmacol,2012,697(1-3):106-116.
36	GAN AM,BUTOI ED,MANEA A,et al.Inflammatory effects of resistin on human smooth muscle cells:up-regulation of fractalkine and its receptor,CX3CR1 expression by TLR4 and Gi-protein pathways[J]. Cell Tissue Res,2013,351(1):161-174.
37	MARTINEZ-HERVÁS S,VINUÉ A,NÚEZ L,et al. Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis[J]. Cardiovasc Res,2014,103(2):324-336.
38	PIRVULESCU MM,GAN AM,STAN D,et al.Subendothelial resistin enhances monocyte transmigration in a co-culture of human endothelial and smooth muscle cells by mechanisms involving fractalkine,MCP-1 and activation of TLR4 and Gi/o proteins signaling[J]. Int J Biochem Cell Biol,2014,50:29-37.
39	POUPEL L,BOISSONNAS A,HERMAND P,et al.Pharmacological inhibition of the chemokine receptor,CX3CR1,reduces atherosclerosis in mice[J]. Arterioscler Thromb Vasc Biol,2013 ,33(10):2297-2305.
40	张阿莲,高霖,程纯,等. 硫化氢对动脉粥样硬化的影响及其与CX3CR1的关系[J]. 中国分子心脏病学杂志,2014,14(1):839-844.
41	CIMATO TR,PALKA BA.Fractalkine(CX3CL1),GM-CSF and VEGF-a levels are reduced by statins in adult patients[J]. Clin Transl Med,2014,3:14.
42	NIE P,LI D,HU L,et al.Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors[J]. PLoS One,2014,9(5):e97009.
43	彭丹丹,邱健. 瑞舒伐他汀对冠心病患者CX3CR1表达的影响[J]. 广州医学院学报,2014,42(2):8-10.
44	ALI MT,MARTIN K,KUMAR AH,et al.A novel CX3CR1 antagonist eluting stent reduces stenosis by targeting inflammation[J]. Biomaterials,2015,69:22-29.
45	XUEYAO Y,SAIFEI Z,DAN Y,et al.Circulating fractalkine levels predict the development of the metabolic syndrome[J]. Int J Endocrinol,2014,2014:715148.
46	SHAH R,MATTHEWS GJ,SHAH RY,et al.Serum fractalkine(CX3CL1) and cardiovascular outcomes and diabetes:findings from the chronic renal insufficiency cohort(CRIC) study[J]. Am J Kidney Dis,2015,66(2):266-273.
47	NJERVE IU,PETTERSEN A,OPSTAD TB,et al.Fractalkine and its receptor(CX3CR1) in patients with stable coronary artery disease and diabetes mellitus[J]. Metab Syndr Relat Disord,2012,10(6):400-406.
48	ZHONG ZX,LI B,LI CR,et al.Role of chemokines in promoting instability of coronary atherosclerotic plaques and the underlying molecular mechanism[J]. Braz J Med Biol Res,2015,48(2):161-166.
49	刘君,雷明明,王妍,等. FKN在急性心肌梗死早期诊断中的作用[J]. 中国医科大学学报,2015,44(4):307-310.
50	NJERVE IU,SOLHEIM S,LUNDE K,et al.Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection[J]. Cytokine,2014,69(1):131-135.
51	刘军锋,李旭,贾克刚,等. LOX-1和CX3CR1与冠状动脉狭窄性疾病关系及其预后价值的探讨[J]. 中华检验医学杂志,2014,37(1):66-71.

参考文献	发表年份	国家	样本量（病例/对照）	基因型（病例/对照）			等位基因（病例/对照）		疾病
参考文献	发表年份	国家	样本量（病例/对照）	VV	VI	II	V	I	疾病
[11]	2001	法国	151/249	97/126	47/104	7/19	241/356	61/142	CAD
[11]	2005	奥地利	720/432	395/246	271/161	54/25	1 061/653	379/211	CAD
[11]	2007	希腊	210/165	111/86	81/59	18/20	303/231	117/99	CAD
[12]	2007	美国	802/658	410/353	336/254	56/51	1 156/960	448/356	ACS
[11]	2008	中国	108/80	70/41	33/34	5/5	173/116	43/44	CAD
[11]	2008	加拿大	149/149	73/63	63/69	13/17	209/195	89/103	CAD
[11]	2008	加拿大	150/149	58/63	77/69	15/17	193/195	107/103	CAD
[13]	2009	奥地利	2 565/728	1 374/372	1 012/283	179/73	3 760/1 027	1 370/429	CAD
[14]	2010	中国	139/90	126/68	13/19	0/3	265/155	13/25	CAD
[15]	2012	印度	152/300	111/150	37/118	4/32	259/418	45/182	CAD
[15]	2012	印度	156/300	96/150	48/118	12/32	240/418	72/182	CAD
[16]	2012	印度	230/300	157/150	61/118	12/32	375/418	85/182	AMI
[17]	2013	意大利	25/22	13/2	10/12	2/8	36/16	14/28	AMI
[17]	2013	意大利	16/22	1/2	10/12	5/8	12/16	20/28	AMI

参考文献	发表年份	国家	样本量（病例/对照）	基因型（病例/对照）			等位基因（病例/对照）		疾病
参考文献	发表年份	国家	样本量（病例/对照）	VV	VI	II	V	I	疾病
[11]	2001	法国	151/249	97/126	47/104	7/19	241/356	61/142	CAD
[11]	2005	奥地利	720/432	395/246	271/161	54/25	1 061/653	379/211	CAD
[11]	2007	希腊	210/165	111/86	81/59	18/20	303/231	117/99	CAD
[12]	2007	美国	802/658	410/353	336/254	56/51	1 156/960	448/356	ACS
[11]	2008	中国	108/80	70/41	33/34	5/5	173/116	43/44	CAD
[11]	2008	加拿大	149/149	73/63	63/69	13/17	209/195	89/103	CAD
[11]	2008	加拿大	150/149	58/63	77/69	15/17	193/195	107/103	CAD
[13]	2009	奥地利	2 565/728	1 374/372	1 012/283	179/73	3 760/1 027	1 370/429	CAD
[14]	2010	中国	139/90	126/68	13/19	0/3	265/155	13/25	CAD
[15]	2012	印度	152/300	111/150	37/118	4/32	259/418	45/182	CAD
[15]	2012	印度	156/300	96/150	48/118	12/32	240/418	72/182	CAD
[16]	2012	印度	230/300	157/150	61/118	12/32	375/418	85/182	AMI
[17]	2013	意大利	25/22	13/2	10/12	2/8	36/16	14/28	AMI
[17]	2013	意大利	16/22	1/2	10/12	5/8	12/16	20/28	AMI

参考文献	发表年份	国家	样本量（病例/对照）	基因型（病例/对照）			等位基因（病例/对照）		疾病
参考文献	发表年份	国家	样本量（病例/对照）	TT	TM	MM	T	M	疾病
[11]	2001	法国	151/249	123/179	25/65	3/5	271/423	31/75	CAD
[11]	2005	奥地利	720/432	514/319	189/100	17/13	1 217/738	223/126	CAD
[11]	2007	希腊	210/165	159/109	48/53	3/3	366/271	54/59	CAD
[12]	2007	美国	806/655	565/447	223/195	18/13	1 148/1 089	259/221	ACS
[11]	2008	中国	108/80	88/59	18/20	2/1	194/138	22/22	CAD
[11]	2008	加拿大	149/149	97/94	49/48	3/7	243/236	55/62	CAD
[11]	2008	加拿大	150/149	92/94	49/48	9/7	233/236	67/62	CAD
[13]	2009	奥地利	2 565/728	1 797/483	706/217	59/26	4 300/1 183	824/269	CAD
[14]	2010	中国	139/90	129/81	10/9	0/0	268/171	10/9	CAD
[15]	2012	印度	152/300	126/191	24/99	2/10	276/481	28/119	CAD
[15]	2012	印度	156/300	124/191	28/99	4/10	276/481	36/119	CAD
[16]	2012	印度	230/300	190/191	36/99	4/10	416/481	44/119	AMI
[17]	2013	意大利	25/22	21/14	4/7	0/1	46/35	4/9	AMI
[17]	2013	意大利	16/22	9/14	7/7	0/1	25/35	7/9	AMI

参考文献	发表年份	国家	样本量（病例/对照）	基因型（病例/对照）			等位基因（病例/对照）		疾病
参考文献	发表年份	国家	样本量（病例/对照）	TT	TM	MM	T	M	疾病
[11]	2001	法国	151/249	123/179	25/65	3/5	271/423	31/75	CAD
[11]	2005	奥地利	720/432	514/319	189/100	17/13	1 217/738	223/126	CAD
[11]	2007	希腊	210/165	159/109	48/53	3/3	366/271	54/59	CAD
[12]	2007	美国	806/655	565/447	223/195	18/13	1 148/1 089	259/221	ACS
[11]	2008	中国	108/80	88/59	18/20	2/1	194/138	22/22	CAD
[11]	2008	加拿大	149/149	97/94	49/48	3/7	243/236	55/62	CAD
[11]	2008	加拿大	150/149	92/94	49/48	9/7	233/236	67/62	CAD
[13]	2009	奥地利	2 565/728	1 797/483	706/217	59/26	4 300/1 183	824/269	CAD
[14]	2010	中国	139/90	129/81	10/9	0/0	268/171	10/9	CAD
[15]	2012	印度	152/300	126/191	24/99	2/10	276/481	28/119	CAD
[15]	2012	印度	156/300	124/191	28/99	4/10	276/481	36/119	CAD
[16]	2012	印度	230/300	190/191	36/99	4/10	416/481	44/119	AMI
[17]	2013	意大利	25/22	21/14	4/7	0/1	46/35	4/9	AMI
[17]	2013	意大利	16/22	9/14	7/7	0/1	25/35	7/9	AMI

[1]	MA Jianguo, ZHU Xiaolin, DING Yongguang, YIN Meng, LI Hongchun. Predictive values of red blood cell distribution width and myocardial markers for acute myocardial infarction in patients with CAS [J]. Laboratory Medicine, 2022, 37(12): 1164-1168.
[2]	KONG Fanbin, YUAN Yong, JI Yong, LI Zheng, CHEN Qi, WU Xiaoming, GAO Hui. Correlation between serum retinol binding protein 4,homocysteine and blood lipid with atherosclerosis [J]. Laboratory Medicine, 2021, 36(5): 467-470.
[3]	LU Yide, WU Jianing, PENG Yibing. Clinical application of serum lipoprotein-associated phospholipase A₂ level in patients with acute cerebral infarction [J]. Laboratory Medicine, 2020, 35(2): 129-133.
[4]	LIU Xiaoni, WANG Ying, LI Taotao, MA Xiaomin, ZHAO Huanlao. Correlation of insulin resistance index and chronic inflammation index in type 2 diabetes mellitus patients with metabolic syndrome [J]. Laboratory Medicine, 2019, 34(9): 826-830.
[5]	CAO Ming, WANG Qijun. Influence of plasma homocysteine level change on atherosclerosis in H-type hypertension patients [J]. Laboratory Medicine, 2019, 34(11): 1007-1010.
[6]	WANG Kaijuan, LI Tiewei, WANG Zongjian, CHEN Xi, GAO Xiaojing, LIN Yahui, ZHOU Zhou, KANG Jinsuo. Correlation between high-sensitivity cardiac troponin T and the characteristics of coronary atherosclerosis [J]. Laboratory Medicine, 2019, 34(1): 11-18.
[7]	BO Lei, SHAN Jigang, ZHAO Zhiwen. Research progress of myeloperoxidase in cardiovascular diseases [J]. Laboratory Medicine, 2017, 32(8): 738-743.
[8]	TONG Minghong, TAO Rongxia, LI Ying, WANG Zi, DING Hui, DENG Chenxia, CAO Yanan, SHENG Huiming. Correlations of apolipoprotein E and lipoprotein（a） with coronary heart disease [J]. Laboratory Medicine, 2017, 32(6): 490-494.
[9]	SUN Yefu, CHEN Guiming, XIA Aiping, ZHANG Zhifeng. Osteoprotegerin expression on aortic atherosclerotic plaques and vessel calcification of diabetes mellitus rats [J]. Laboratory Medicine, 2017, 32(4): 333-337.
[10]	LIU Junfeng, JING Rui, LIU Yaning, HUO Qianyu, LIU Zhili, JIA Kegang, LI Yongshu, HAN Xuejing, LIN Wenhua, LIU Yunde. Correlation of the expressions of LOX-1 and CX3CR1 from monocytes and proximal/middle coronary artery stenosis [J]. Laboratory Medicine, 2017, 32(11): 1024-1030.
[11]	LEI Ming, BAI Ju, WU Jianhua, XIA Danni, ZHENG Ruidong. The influence of Helicobacter pylori infection on serum homocysteine level in patients with carotid atherosclerosis [J]. Laboratory Medicine, 2015, 30(9): 894-897.
[12]	JIANG Xiaohong. Clinical significance of detecting serum adiponectin in patients with acute myocardial infarction [J]. Laboratory Medicine, 2015, 30(6): 585-587.
[13]	YANG Wendong. Correlation research on serum ferritin and homocysteine levels with carotid atherosclerosis in essential hypertension patients [J]. Laboratory Medicine, 2015, 30(3): 227-229.
[14]	WU Rongqiang, WANG Sujian, WANG Shizhong, ZHOU Haijun, QI Chunjian. The influence of beta-glucan on TNF-α,IL-8 and IL-12 in monocytes [J]. Laboratory Medicine, 2015, 30(3): 280-283.
[15]	HU Dong, WU Qian, CHEN Gang, ZHU Huaqiang, XIANG Lixian, ZHANG Wei. Influence of Helicobacter pylori infection on carotid atherosclerosis in elderly patients with hypertension [J]. , 2014, 29(9): 918-921.